Every 424B that INVO Fertility, Inc. (IVF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVF filings page.
INVO Fertility, Inc. is registering up to 20,000,000 shares of common stock for resale by Alumni Capital LP under an Any Market Purchase Agreement. The company may sell shares to Alumni over time for up to $15 million in gross proceeds, potentially increasing to $50 million by mutual agreement.
INVO had 2,295,035 shares outstanding as of July 23, 2026; if all 20,000,000 registered shares were issued, they would represent about 89.7% of the then-outstanding stock, significantly diluting existing holders. Alumni cannot own more than 9.99% of outstanding shares at any time, and shareholder approval has been obtained to exceed Nasdaq’s 19.99% exchange cap.
Share purchase prices are set at formula discounts to recent trading prices based on VWAP or lowest traded prices. INVO expects to use any proceeds for acquiring additional fertility clinics, clinic development, capital expenditures, working capital, and general and administrative expenses. The stock trades on Nasdaq under the symbol IVF, and investing in these securities is described as highly speculative and high risk.
INVO Fertility, Inc. is registering for resale up to 9,467,456 shares of common stock issuable upon exercise of an Inducement Warrant held by Armistice Capital Master Fund Ltd. The warrant carries a $1.59 per share exercise price, and INVO may receive up to $15,053,255 if it is fully exercised.
INVO will not receive any proceeds from Armistice’s resale of shares, only from warrant exercises. The company plans to use any net proceeds primarily to acquire additional fertility clinics and related businesses, fund capital expenditures, and support working capital and general corporate purposes.
Armistice’s warrant is subject to a 9.99% beneficial ownership limitation, and INVO’s common stock traded at $1.37 per share on Nasdaq on January 30, 2026. The prospectus warns that issuance and resale of these shares could dilute existing holders and pressure the stock price.
INVO Fertility, Inc. filed a resale prospectus covering up to 8,345,774 shares of common stock to be offered and sold by Five Narrow Lane LP. The shares consist of stock issuable upon conversion of the Series C-2 Non-Voting Convertible Preferred and upon exercise of an Inducement Warrant.
The company is not selling any shares in this offering and will not receive proceeds from sales by the selling stockholder. INVO may receive up to $344,000 only if the warrant is exercised. Sales may occur on Nasdaq or through negotiated transactions at market or varying prices.
The Series C-2 Preferred and the warrant include a 9.99% beneficial ownership limitation. Shares outstanding were 5,624,012 as of October 13, 2025; this is a baseline figure, not the amount being offered. The filing notes potential dilution from conversions/exercises and lists standard resale methods, including brokerage transactions and short sales after effectiveness.